My Rehovot ( ISSN 1817-101X )

Apolitical journal on every aspect of life in Rehovot, Israel

Home | Archive | Rehovot.org | BizDir | rBB | rForum | Rentals | Property | Jobs | Makolet | Flowers | Car for Sale | TV | Photo Albums | Arts | Events | Obituaries/Guest Books | Sport | Bulletin Board (Rus) | Dating (Rus) | Advertise | Contacts
_ _Press go button to proceed with your subscription request          This is a link to MyRehovot.Info in Russian  This is a link to MyRehovot.Info in Hebrew  This is a link to MyRehovot.Info home in English
Visit Google Scholar, new search of quality scholar literature by Google   _

Fresh'n'tasty bread at Rehovot's authentic Brand New Berad house. Come in today for a degustation or a cup of coffee

Thursday, August 31, 2006

IBM To Set Up Software Lab In Rehovot

Global company expanding its research activity in Israel; new laboratory to consolidate three software development groups operating in Rehovot, Jerusalem

IBM Corp. is expanding its research activity in Israel. The company announced that it was setting up a third software laboratory locally.

The new laboratory will consolidate three software development groups operating in Rehovot and Jerusalem, which are run by teams of companies IBM acquired in recent years.

IBM’s R&D activity in Israel is one of the longest standing in the country. IBM’s Haifa research center was established over 30 years ago and is one of the company’s largest centers outside the US. The IBM Israel Research Lab has over 400 employees. The second development laboratory, which focuses on semiconductors, is located in Ramat Hahayal, Tel Aviv, and Haifa.

The new laboratory, based in Rehovot and Jerusalem, will bring the total number of IBM research and development staff in Israel to 650 employees.

Source: IBM to set up 3rd software lab in Israel. YNet.co.il (30 August 2006) [

Tuesday, August 29, 2006

News Archive 2001: Violence in Rehovot Schools Shocked The Police

VIOLENCE in Rehovot and Rishon Lezion schools has become a matter which no longer causes the police to bat an eyelid but the number of acts of violence over recent weeks has shocked even them, reports Arim Hebrew weekly.

Rehovot spokesman Zvi Eyal said: "Rehovot is the first city in the country to give out these kits. We have put up special tins in which to deposit the waste. Two inspectors patrol the parks with a camera every day to locate offenders."

VIOLENCE against women is up in Rishon Lezion, down in Rehovot There was an 18% increase in the number of files opened in Rishon Lezion for violence against women from the beginning of the year compared to the same period in the year 2000.

Source: Harari R. Focus on Rehovot & Rishon Lezion. Jerusalem Post City Lights Archive (30 Nov 2001) [FullText]

Sunday, August 27, 2006

"Thirty minutes south of Tel Aviv, a small municipality with manicured roundabouts and quiet streets welcomes visitors with gurgling stone fountains and bougainvillea-lined avenues. Amidst the sparkling new high-rises and single-family suburban homes, a spattering of dilapidated houses and old monuments attest to the city's rich historical past. Tucked unassumingly in the gap between Rishon Lezion and Rehovot, Ness Ziona was one of the first Jewish settlements in Palestine.

Today, on a hot morning in July, as the street cleaners hum around and twisting yellow construction cranes hover in the distance, Larry Shapiro offers an anecdote to sum up the locale.

"A guy on his way to Ness Ziona gets to Rishon and asks for directions. 'Keep going,' they tell him. Then he gets to Rehovot and asks again. 'You've missed it,' he's told."

Shapiro, an 85-year-old widower who recently made aliya from the United States to Ness Ziona, worked in radio for years and has a deep, soothing voice. He chose Ness Ziona because his relatives were among the first pioneering families to settle here, and many relatives still remain.

"My cousin-in-law, Tova, married my cousin Levy Kovarsky in 1946. He was the son of my aunt, Jenny, who was brought from the United States to Ness Ziona to be raised by her uncles after much of the family fled the pogroms in Russia," explains Shapiro as he adjusts a pair of dark glasses to shade his eyes from the blaring mid-day sun. He notes that on his first visit to Ness Ziona in 1969, the streets were still just sand and what is now developed land was entirely devoted to orange groves.

Tova, who lives in a new apartment building on Rothschild Street, has an even further-reaching memory, back to the time when only a few thousand Jews lived in Ness Ziona among hostile Arabs.

"Until 1948 we lived side by side, but we [the Jews] were the minority, and it was always a struggle," says Kovarsky as we walk down the street to Beit Rishonim, the first community center in Ness Ziona.

Built in 1907, 24 years after Reuben Lehrer bartered his land in Odessa for a plot in Palestine near Jerusalem, Beit Rishonim originally served as the schoolhouse, the synagogue, the city council building and the community gathering spot. Today, it houses pictures of the first settlers, artifacts and historical documents. In a dark room to one side, a short narrative tells the story of Ness Ziona's difficult battle for existence as lights shine on a miniature model of the original town and its first settlers.

WHEN LEHRER, an Orthodox Jew who wanted to work the land and study the Torah, arrived in 1883 with his eldest son, Moshe, he was surprised to find an abandoned house with no water supply far away from Jerusalem. Nevertheless, determined to populate Zion, he returned to Russia to bring his wife and remaining children back to the terrain where Ness Ziona still stands.

In 1887, after the Lehrer family had begun to cultivate grapes, almonds and bees, they posted signs at the arrival gate in the Jaffa port beseeching fellow Jews to help them settle their land and found a community that would first be called Nahalat Reuben.

Golda Miloslawsky, famous for the beauty of her roses and thriving vineyards, was the first woman to heed Lehrer's call. Soon, the two families were joined by Aaron Eisenberg, a master stone-cutter who later founded Rehovot, Abraham Yalowsky, a Talmud scholar and blacksmith who was murdered by Arabs in the defense of his home a few years after his arrival, Zalman Fisher, who was also murdered by Arabs in his orange groves and survived by his wife Bella Fisher, and Michael Halperin, the organizer of a group of Mahaneh Yehuda horsemen.

At the circumcision of Eisenberg's first-born son, Halperin presented the now-famous white flag with two horizontal blue stripes and the Star of David. In gold embroidery along the bottom were the words 'Ness Ziona.' Since Halperin planted it in the ground as a symbol of independence from the neighboring Rothschilds, the settlement has been known by this name, meaning 'Miracle of Zion.'

Halperin later offered this same flag, minus the words Ness Ziona, to the first Jewish Congress in Basel, which was presided over by Theodor Herzl in 1897. It was later adopted by the State of Israel as the national flag.

By the 1920s, despite difficult struggles against neighboring Arabs, malaria and challenging agricultural conditions, Ness Ziona was thriving and prosperous. Lining the walls of Beit Rishonim are old black-and-white photos of camels carrying boxes of oranges to the market in Jaffa and the first Jewish pioneers toiling in the fields.

Tikva Rosenmann, who runs the Beit Rishonim museum, is the great-granddaughter of Reuben Lehrer.

"This is my grandparents' ketuba," she says, pointing to a framed document behind one of the glass casings. Alongside antique agricultural tools are shelves lined with musical instruments, sports equipment and household items.

"When I was a little girl, my grandmother would give us quinine pills every morning," says Rosenmann pointing to a brass mortar and pestle.

"To ease the bitterness, she crushed them up and fed them to us with honey we gathered ourselves. In those days, we used to throw water on the sand streets to keep the dust down," she says, a faraway look in her eyes. "The founders brought a strong Russian ideology with them, but by my generation, some Sephardi families and a small number of Yemenite families were here too, and we were one big family."

Today, the sand streets have given way to asphalt and most of the town's original buildings have either been restored as historical sites or torn down to make way for new high-rises. After 123 years, the city's population is still relatively small - around 30,000 - with an annual growth rate of two percent.

"Demographically, the population of Ness Ziona mirrors the averages of the State of Israel - without the Arabs," says Yossi Shavo, the well-liked mayor of Ness Ziona who has been in office for the past 13 years. "We have a diverse population with people from everywhere."

"As a child, I remember families from Iran, Morocco, Yemen and Iraq moving to Ness Ziona in the 1950s and '60s and living in shacks at the edge of town until they could afford to buy something of their own," says Liora Kovarsky-Kraus, a retired high-school literature teacher who taught for over thirty years in Ness Ziona. "The mentality at that time was different. There were no government agencies helping new immigrants. People knew they would have to work hard to afford a house, so they did, and they eventually moved into places of their own."

Yet, while residents may have originally come from all over the world, apart from Ethiopians and Russians, few new immigrants make their way to Ness Ziona today. Only one ulpan exists in the city, and it caters to the Ethiopians because they are the only immigrant population large enough to justify ulpan classes. According to Kovarsky-Kraus, the Ethiopian immigrants are granted government subsidies that attract them to the area and make housing affordable. For other new immigrants wanting to learn Hebrew, the closest option is in Rehovot. "I take a cab to my ulpan in Rehovot twice a week because there isn't one in Ness Ziona that I can attend," says Shapiro, who is still struggling to master Hebrew..."

FullText of this article is available at the tourism.jpost.com, see the reference below.

Source: Meredith Price. On Location: The Miracle of Zion. (14 August 2006) [FullText]

Wednesday, August 23, 2006

Rehovot Born Author and Israel Prize Laureate S. Yizhar Dies at 90

Israeli writer Yizhar Smilansky better known by his pen name S. Yizhar died Monday morning of heart failure. He was 90 years old.

His pen name was given him by the poet and editor Yitzhak Lamdan, when in 1938 he published Yizhar's first short novella "Ephraim Hozer Leaspeset" ("Ephraim Goes Back to Alfalfa") in his literary journal "Gillionot". From then on, Yizhar signed his works with this pen name.

Yizhar was a great innovator in modern Hebrew literature. His writing characteristically combined long formulations of high-level prose, mixed with street slang.

Vice Premier Shimon Peres knew Yizhar through their joint political activity in Israel's Knesset. Peres said "my friend Yizhar, that went along with me a long way and for many years, made the brand new state of Israel into the intellectual homeland of the Israeli people. There never was another man that had his penetrating vision and wondrous articulation. He made the Hebrew language into a celebration and a challenge simultaneously. He saw things deeply and was a part of them."

In his eulogy, Peres made reference to Yizhar's great contribution to Hebrew literature and said, "Since Yizhar, Hebrew literature is not what it used to be. He was involved in real decisions for Israel's people, he loved the people, his sons, his army as well as peace, and he never gave anyone any breaks because of his love. Yizhar gave Hebrew literature a flavor that will never fade."

Yizhar was born in 1916 and spent his childhood in Kibbutz Hulda, Tel Aviv and Rehovot. His parents were among the first Jewish settlers in the area.

Yizhar attended a teachers' seminary in Jerusalem and later taught in Yavniel, Ben Shemen and Rehovot.

In 1948 he served as an officer in the intelligence unit of the military. One year later, he was elected to the first Knesset in founding prime minister David Ben-Gurion's Mapai party, and served as a Knesset member on the party's list for four additional terms. His sixth term as a member of the Knesset was for Ben-Gurion's breakaway Rafi party.

Yizhar studied at Hebrew University in Jerusalem and at Harvard University in Massachusettes, and was awarded a PhD. He later taught at Hebrew University, as well as Tel Aviv University as a literature professor.

After the publication of his first novella in 1938, Yizhar published numerous other novellas, which solidified his status as one of the foremost Israeli-born writers. His first collection of short stories "Hachorsha Bagiv'ah" ("The wood on the hill") saw light in 1947. In 1948 the collection won the Ruppin prize for literature.

Towards the end of Israel's 1948 Independence War, Yizhar published "Hashavuy" ("The captive") which stirred much controversy. The collection of stories "Hirvat Hazaa" in 1949 was also very controversial.

In the late 1950s his massive work "Yemey Ziklag" ("Days of Ziklag") appeared, comprising two volumes and more than a thousand pages. This work completely changed the outlook for Hebrew prose on the one hand, and "war literature" on the other. The work earned him the Israel Prize at only 43, making him one of the youngest recipients of the prize.

In the 60's Yizhar published "Sipurey Mishor" ("stories of a plane"). In the years that followed, Yizhar did not write fiction, but concentrated on publishing articles and books about literature and education.

In the 90's Yizahr published six consecutive books. For these he was awarded many literature prizes and honorary doctorate degrees.

Source: Author and Israel Prize laureate S. Yizhar dies at 90. Haaretz (21 August 2006) [FullText]

Monday, August 21, 2006

News Archive: Ramle Magistrates Court Refrained From Sentencing Former Rehovot Mayor

Ramle Magistrates Court refrained from sentencing former Rehovot Mayor Ya'akov Sandler and other senior officials of the last Rehovot Municipality administration to a prison sentence after they pleaded guilty to charges filed against them by the Ministry of the Environment, and accepted the defense plea to suffice with sentencing them to community service, reports Bamakom Hebrew weekly.

Source: Harari R. Focus on Rehovot & Rishon Lezion. JPost.com (22 March 2002) [Fulltext]

Saturday, August 19, 2006

News Archive: My Rehovot Headlines November 2001

Rehovot police are investigating a complaint of fraudulent collection of money supposedly for the families of three MIA Israeli soldiers, St.-Sgts. Binyamin ([Benny Avraham]) Avraham and Omar Suwayed and Sgt.

The decision of school principal Nava Federski of the Ma'a lot Meshulam School in Rehovot to combine the memorial day service for Yitzhak Rabin with that for the matriarch [Rachel], wife of the Jewish patriarch Jacob, was the cause of much consternation in the local education network, re- ports Arim Hebrew weekly.

Among the 2,600 participants in The Young Entrepreneurs Do Business program which got underway this week are pupils from high schools in Rehovot and Rishon Lezion.

Source: R. Harari. Focus on Rehovot & Rishon Lezion. JPost.com Archive (2 Nov 2001) [FulllText]

Thursday, August 17, 2006

News Archive: Minitsry of Housing Cut Rehovot's Kiryat Moshe Renovation Projext

The Ministry of Housing is to invest only NIS 1 million in the renovation project for the Kiryat Moshe neighborhood in Rehovot instead of the NIS 4 million originally promised, reports Bamakom.

When Kiryat Moshe, a predominantly Ethiopian immigrant neighborhood, joined Project Renewal two years ago it was agreed that NIS 8 million would be invested in physical renovation of the area: NIS 4 million from the Ministry of Housing and NIS 4 million from Rehovot Municipality.

Source: Rosalyn Harari. Focus on Rehovot & Rishon. JPost.com (5 October 2001) [FullText]

Tuesday, August 15, 2006

Municipality News Archive 2001: Mayor Wantes All Rehovot Rabbis Be Equal

Rehovot Mayor Shuki Fohrer has called upon the Ministry of Religious Affairs to bring the salary and working conditions of the rabbi of the city's Ethiopian community, Harav Yitzhak Zagai, in line with that of Rehovot's other rabbis. He has been joined in his efforts by Chairman of the Histadrut in the Rehovot area, Amir Yaron, who has demanded that the Labor Court take action to rectify the injustice, reports Bamakom Hebrew weekly.

Chairman of Rehovot religious council Zerah Meshulam says that Harav Zagai already enjoys preferential conditions. "There is a government decision to give Ethiopian Kes and rabbis salaries for work in the community and he gets exactly what the Ministry for Religious Affairs and the government have determined. If Harav Zagai were not Ethiopian, he would have to wait a long time until a position for rabbi came up."

Currently, residents of the area south of Rehovot, including Mazkeret Batya, Kiryat Ekron and Gadera, are forced to travel to Rehovot in order to take the train, which passes directly by Mazkeret Batya.

Source: Rosalyn Harari. Focus on ...Rehovot & Rishon Lezion. JPost.com City Lights Edition (7 September 2001) [FullText]

Sunday, August 13, 2006

News Archive 2003: Religious Factions Do Well in Rehovot

Rehovot's Shuki Fohrer was elected for a second term of office with 57% of the vote. Hanania Weinberger gained 26% of the votes cast; Shmuel Fisher, 9% and Ruth Brodie, 8%. Only 39% of those eligible to vote exercised their right.

Source: Rosalyn Harari. Religious factions do well in Rehovot (7 November 2003) [Fulltext]

Thursday, August 10, 2006

Rehovot's D-Pharm To Perform a Trial of a Medicine to Treat Acute Stroke Patients

REHOVOT, Israel (1 August 2006) - D-Pharm announced today completion of enrollment in its Phase IIb clinical trial of DP-b99. DP-b99 is a unique neuroprotective drug that addresses the array of damaging processes occurring in the brains of stroke patients. The Phase IIb trial results are expected to be available towards the end of 2006 following completion of the 3 month follow-up period.

"Patient enrollment into stroke trials is notoriously difficult to plan, therefore, I'm very satisfied that we've managed to complete enrollment without major delays. D-Pharm is indebted to all the investigators and other team members in the study sites in Germany, Israel and South Africa, whose dedicated efforts and meticulous work enabled the timely completion of this task" said Dr Gilad Rosenberg, D-Pharm's VP, Clinical Development.

The current double blind, placebo controlled, multi-center, international trial is designed to reconfirm the efficacy and beneficial effect of DP-b99 previously observed in stroke patients, as well as to strengthen and extend the safety data obtained from the Phase IIa study. The study enrolled patients with ischemic stroke accompanied by language dysfunction, visual field defect or inattention with a baseline NIHSS score of 7 to 20. Patients were recruited in 25 centers in Germany, Israel and latterly also in South Africa. In this trial DP-b99 was administered intravenously, once daily, over 4 days with the first administration up to 9 hours following stroke onset. The patient group is stratified into those treated within six hours or within six to nine hours following stroke onset. Thus, in addition to confirming safety and efficacy, D-Pharm expects this study to clearly define the optimal patient population and therapeutic window for DP-b99.

Clinical, laboratory and electrocardiographic safety data has been monitored throughout the trial by an independent Drug Safety Monitoring Board. To date, no differences have been found between the placebo and active drug groups with respect to adverse events or other safety measures, and following each of the Board's reviews the recommendation was to continue the study as planned. Cato Research served as the clinical research organization for this study.

Stroke is the leading cause of neurological disability worldwide and reflects a considerable unmet need in effective acute stroke therapy, which DP-b99 aims to address.

DP-b99

DP-b99 is a discovery product, rationally designed using D-Pharm's proprietary technology, Membrane Active Chelators (MAC). Considerable evidence suggests that redistribution of metal ions and disturbances in metal ion homeostasis are key components in the cascade of events underlying cell damage in stroke. In the first hours post-stroke, ion disturbances cause excitatory cell damage and in the days and weeks following they contribute to edema, inflammation and cell death. D-Pharm is developing a novel approach to neuroprotection based on selective modulation of calcium, zinc, copper and iron homeostasis in the vicinity of cell membranes.

In earlier Phase I and II clinical trials DP-b99 was proven to be safe both in healthy young and elderly volunteers and in stroke patients. Efficacy evaluation in Phase IIa demonstrated noteworthy improvements in clinical stroke outcome assessed with the NIH Stroke Scale (NIHSS) 2, 7 and 30 days after stroke in patients treated with DP-b99 within 12 hours of the onset of stroke symptoms.

Source: D-Pharm LTD [FullText at DrugNewswire]

Monday, August 07, 2006

Worrying of Israel, Rehovot - Half a World Away

Ayelet Shavit and her husband Ran of Davis show their children photos of their grandparents in Israel. The 3-year-old twins are Tal and Ofri; Ayelet is holding 4-week-old Rotem. Ayelet, who grew up in Israel, moved to Davis 10 months ago to complete her postdoctorate in philosophy.

As fighting rages between Israel and the Hezbollah militant group in Lebanon, several Davis residents worry about the safety of family members living in Israel.

Shulamit Glazerman’s sister, Susan Gabel, lives with her husband and their 10 children in the northern mountaintop town of Safed, about 7 miles from the country’s border with Lebanon. When fighting started July 12, the town was targeted.

“They started to come under rocketfire by Hezbollah,” Glazerman said.

A rocket landed in a neighbor’s front yard. The windows were blown out of Gabel’s downstairs neighbor’s apartment. And they found shrapnel in a kiddie pool on their deck. Rocks and debris from a nearby strike showered down on one of her nephews as he made his way home from the synagogue.

Glazerman read that about 200 people from this town alone have been treated for shock. Some fled the town, but at first, Gabel decided not to leave because it would be difficult with so many children.

They stayed for three days. Then, Glazerman recalled her sister saying, “We can’t live like this.”
In the last day they were home, Gabel and her family could use only the interior part of their apartment, staying away from outer walls for fear of being injured by the blasts.

“They just had to get out,” Glazerman said. “I was very concerned for their safety.”

They finally escaped to a suburb of Jerusalem and found an apartment to rent for a few weeks from a family vacationing in the United States. Gabel’s children aren’t in school. Their lives are in limbo. The family is watching the news and hoping the rocketfire will cease, so they can return home.

“The whole situation is very upsetting,” Glazerman said. “It’s upsetting what Hezbollah is doing. Hezbollah wants to destroy Israel. They’re targeting civilian populations intentionally. And it’s upsetting that Israel is having to respond. But they have to fight them.

“They don’t have a choice because they have to defend themselves and no other entity in the world has the ability or the will to fight Hezbollah. They can’t let this go on.”

Glazerman’s family is planning to go to Israel in about a month and stay for a year while her husband, Jay Rosenheim, an entomology professor at UC Davis, is on sabbatical. They are watching the news closely, trying to decide whether to go ahead with the trip to Rehovot, a city about 20 minutes southeast of Tel Aviv.

“I’m not expecting that it (the fighting) would stop, but we’re hoping that things would stabilize and not escalate,” Glazerman said.

‘Doesn’t leave my mind’

Ayelet Shavit, who grew up in Israel, moved to Davis 10 months ago to complete her postdoctorate in philosophy at UCD. Her parents, grandfather and nephew are still there.

Shavit constantly worries about the safety of her family in Israel. She talks with them by video phone on the computer. In a 20-minute conversation, she hears three or four bombs exploding and her parents’ house shakes. They are OK, but then she hangs up and begins worrying that maybe a bomb is falling on them at this moment or the next.

“It doesn’t leave my mind. It’s there all the time,” Shavit said.

Almost two weeks ago, a bomb landed at the entrance to her nephew’s home in Maayan Baruch, a kibbutz, which is a kind of commune. Luckily, he was visiting his parents at the time, but the house was destroyed.

“It’s just all ruins. It’s frustrating sitting here, hearing the news. It’s just a horrible feeling,” Shavit said of being far away from family and not able to help or do anything.

Shavit knows what it’s like to live with terrorist bombings. She grew up in the kibbutz of Kfar Giladi, a mile from Lebanon. While her community was usually quite safe, terrorist bombing was a constant threat.

“It’s part of your life,” Shavit said. “Once every few months it would happen.

“You get used to it. You just grow up knowing when the whistle comes, you know exactly how many seconds you have to run,” Shavit said. “You learn from the whistle, what kind of bomb or rocket it is.”

Shavit said bomb shelters were located every 50 yards or so around her kibbutz, about the size of the UCD campus. Once, a bomb fell next to her parents’ house. Another time, a bomb fell on top of the bomb shelter in which Shavit was sitting. The shelter shook, but no one was hurt inside.

Even more than the bombing, she was afraid of kidnapping by the terrorists. When she was 5 or 6 years old, a militant group tried to steal some babies from a neighboring kibbutz. A baby and an adult were killed in the ordeal.

Not long after, a group was captured at the border with maps of Shavit’s kibbutz. A circle was drawn around one of the classrooms. It was believed they planned to kidnap children from her kibbutz.

After these incidents, the children were no longer allowed to sleep together in a community nursery room as had been the practice. Instead, they stayed with their parents.

Deep-seated fears

As she grew up, Shavit feared being taken hostage by a terrorist group.

“Wherever I went, I looked for a place to hide. What would happen if he (a terrorist) came now,” Shavit said. Even in Davis, Shavit finds herself looking for a hiding place or escape route in every room she enters.

Shavit watches the news about the current fighting and asks herself, “why?”

“No one wants this war. We don’t want it. I’m sure the Lebanese don’t want it. It’s just so sad,” Shavit said of civilians being killed on both sides.

Shavit is thankful that her three sons — 3-year-old twins and a 1-month-old — are safe here rather than in the war zone.

“I’m happy that my kids are not going through what I went through, but I’m also sad that they’re away from family through all this,” Shavit said.

She plans to stay in Davis with her husband and children for another 18 months and then return to Israel when the situation is hopefully improved.

“I still do have hope. It’s a bad time now, but I’m sure it won’t last. It’s too bad to last. Too many are dying and suffering for this to go on,” Shavit said.

“I just hope for better days. I hope we Israelis and Arabs won’t lose hope that something better will happen,” Shavit said, adding that her greatest fear is that both sides will give up on dreams of peace and allow extremists to control their lives.

Source: Sharon Stello. Worrying, half a world away. Davis Enterprise .net (3 August 2006) [Fulltext]

Sunday, August 06, 2006

Rehovot Father Tragedy: Family, friends mourn fallen Golani soldiers

Father of First Sergeant Daniel Shiran: ‘You understood in a second what takes other people an entire lifetime to understand’; First Sergeant Omri Elmakis’ family: He loved the army and wore a Golani t-shirt even at home and in social events

First Sergeant Omri Elmakis, 21, of Ramle and First Sergeant Daniel Shiran, 20, of Haifa, both Golani Brigade soldiers, were killed early Friday in clashes with Hizbullah gunmen in south Lebanon.

Shiran was laid to rest in the afternoon.

“You were always successful, brilliant,” his father Avinoam said in his eulogy. “You understood in a second what takes other people an entire lifetime to understand. Even when you were about to enter Lebanon, it was obvious to me that you realized the meaning of it. You were tall, handsome, almost 1.9 meters tall (6 ft. 2 inches) and weighed 90 kg (about 200 pounds) – almost all muscle. It was difficult to carry you here, Daniel.”

Shiran was recently stationed in Jenin, Gaza and then Lebanon. He is survived by his parents and his younger brother and sister.

The father, a former paratrooper, said regarding the incident in which Daniel was killed: “We know that at 1:09 a.m. he was operating with his platoon. They told us that they entered on foot at night and that he was positioned in the front with his platoon commander, who is seriously injured. Another friend that we did not know was killed. They told us he entered a zone filled with bombs.”

'He followed in my footsteps'

Following four consecutive weeks away from home, Omri Elmakis finally went on leave and spent the past weekend in his Ramle home.

His good friend Ido Atal said “After spending 30 days in Gaza Omri called me on Friday and asked that I come pick him up. On Sunday he went to Lebanon.

Atal said to Omri during their last conversation, “All of your friends are proud of you; we are waiting for you at home. Don’t do anything foolish.”

“Omri was a funny guy, a sort of prankster,” he said. “We said that after the army we would make a ton of money, fly off to South America and forget about everything.

Family members said Omri loved the army, and wore a Golani t-shirt even at home and in social events.

His uncle, Nissim Elmakis: “He was not willing to serve in any unit other than Golani; he followed in my footsteps.”

Omri lived with his mother Rina and younger sister in Ramle. His father Ilan lives in Rehovot, and the two met last Friday.

Omri is survived by his parents, two brothers and a sister.

Source: Keren Nathanzon. Meital Yasur Beit-Or contributed to the report. Family, friends mourn fallen Golani soldiers. Ynet English (4 August 2006) [FullText]

Saturday, August 05, 2006

US National Academy of Sciences Member Rehovot's Michael Sela Says Weizmann Scientists Have Bad Ethics

"NEW YORK (AP) - The company at the heart of the Martha Stewart stock scandal is in the midst of a bitter patent dispute that threatens its bottom line and has led some world-renowned cancer researchers into a courtroom for a highly unusual showdown.

A judge in Manhattan federal court is deciding who is the rightful owner of a patent used for ImClone Systems Inc.'s blockbuster cancer drug Erbitux. A team of three esteemed scientists from Israel who pioneered a cancer treatment technique claim a former colleague stole their idea and was credited on a patent now owned by Aventis Pharmaceuticals Inc. and licensed to ImClone.

At stake is the future of ImClone, the company whose founder, Sam Waksal, is serving a prison sentence for his role in the stock scandal that also ensnared Stewart.

Erbitux, initially approved to treat colectoral cancer and later expanded to treat head and neck cancer, has contributed heavily to ImClone's success, although the company is facing serious competition from a drug by rival Amgen Inc. that is expected to hit the market in the coming months. Still, ImClone posted robust earnings Thursday thanks to strong sales of Erbitux, which provided about half of the company's total revenue.

But any future earnings could be clouded by the patent lawsuit.

In the 2003 suit, Yeda Research and Development Co. of Israel sued ImClone -- which has an exclusive license for the formula used in Erbitux to inhibit tumor cells -- and Aventis, claiming three of its researchers should be named as the inventors. The current patent names Dr. Joseph Schlessinger, Chairman of Pharmacology at the Yale School of Medicine, as the inventor along with six others, three of whom even the defense has agreed do not belong on the patent.

One of the Israeli researchers, Michael Sela, testified that he considers Schlessinger ``a superb scientist, a very good lecturer,'' and had thought of him as a friend and colleague before ``the bad moment.''

``I have a problem with his ethics,'' said Sela, a professor for 56 years at the Weizmann Institute of Science in Rehovot, Israel. Schlessinger was a longtime researcher at the institute.

In recent weeks, U.S. District Judge Naomi Buchwald has heard testimony from Sela, Schlessinger and other top cancer researchers. She has not yet ruled, and it is not clear when she might do so. But she was critical of many of the arguments presented by lawyers for ImClone and Aventis during closing statements Wednesday.

The consequences could be huge for ImClone if Buchwald rules in favor of the Israeli researchers.

At one point Wednesday, plaintiffs' lawyer Nicholas Groombridge said ImClone stands to lose its exclusivity with the technique covered by the license if Yeda's scientists are credited, freeing Yeda to license the patent to other drug companies. If Schlessinger is taken off the patent -- something the judge indicated was a possibility -- ImClone would not have a license anymore for the drug, he said.

``I presume there would be a negotiation and a deal would be reached,'' he said. ``It is not the intent of Yeda to keep anybody off the market.''

A lawyer for Aventis later noted that one trial witness had remarked that hundreds of millions of dollars were at stake for Yeda and ImClone. Erbitux is distributed in the U.S. by Bristol-Myers Squibb Co., and had U.S. sales of $413 million last year.

Several times, the judge indicated she believed ImClone and Aventis should have settled when Yeda approached the company before trial to seek a deal. ``I cannot decide this based on what the economic consequences may be. That's the risk you take when you don't resolve it,'' she told the Aventis lawyer.

She seemed poised to at least put the Weizmann scientists on the patent, telling one defense lawyer: ``One might wonder why you didn't put the Weizmann people on your patent in the first place.''

Schlessinger is credited with providing an antibody that, when combined with chemotherapy drugs, sometimes has stopped cancer from growing. But aside from the antibody, ``everything else was ours,'' said Sela, the former president of Weizmann and the inventor of the most widely used drug for treating multiple sclerosis.

He said it was the other researchers -- and not Schlessinger -- who came up with the idea to combine the antibody with the chemotherapy medication -- which served as the framework for the invention of Erbitux.

Sela said he had never paid much attention to patents.

``I don't mind if I don't take a patent, unless it's stolen from me. Then I have to react,'' he said. ``At the beginning, when I first saw it, I was in a state of shock. I mean, money is not important, but my name and my science, my honor demanded'' that he be put on the patent.

Dr. Esther Aboud-Pirak, another of the three Yeda researchers, said she was 27 years old and disinterested in patents when she did the bulk of the research work on the method.

Under cross examination, Aboud-Pirak grew testy as she acknowledged that each of the three researchers could share in any money Yeda receives as a result of the litigation.

``I don't think anybody spoke about money here,'' she said. ``We are speaking about our rights to be the author of the work that we have done.''

Schlessinger testified that he contributed little to a 1988 paper Aboud-Pirak wrote on the successful tests. And he acknowledged that his antibody was made with a cell line taken from the Weizmann Institute.

The doctor said he acted properly though.

``We provided the conceptual foundation for the entire field,'' he said. ``We have really generated the only unique material here.''

George Badenoch, a lawyer for ImClone, told the judge that Yeda did nothing to pursue the claim from 1988 -- when the researchers wrote a paper on the subject -- to several years ago, after they learned a patent was issued in 2001.

``It's not proper now that we have got a blockbuster product for them to come in and say, `Hey, now we want to participate, now we got to be paid.'''"

Source: ImClone, cancer drug embroiled in bitter patent dispute. Mercury news (20 July 2006) [FullText]

Also see:

Rehovot's Cancer Scientist and Weizmann Institute Graduate School Dean Yosef Yarden Joins Israel Biotech Firm as Scientific Advisory Board Member. My Rehovot (21 June 2006) [FullText]

President of the Non-profit Weizmann Institute Becomes Rehovot's Biotech Firm Top Official. MyRehvot.info (11 June 2005) [FullText]

Wednesday, August 02, 2006

Rehovot Scientists Cracks Code of DNA Strand

"A research team headed by Weizmann Institute scientists has succeeded in cracking the genetic code that sets down the rules for where on the DNA strand tiny spheres called nucleosomes are located. Their findings appeared Thursday in the prestigious journal Nature.

Nucleosomes provide the lowest level of compaction required to fit DNA into the cell nucleus. They are made up of DNA and four pairs of proteins called histones, and are important in regulating the transcription (the transfer of genetic information from DNA to RNA, which enables the cell to follow the gene's instructions) of DNA by preventing RNA polymerase from accessing the promoter regions of genes not needed by the cell. If the requirements of the cell change, enzymes known as remodeling factors can remove or change the position of the nucleosome to allow access.

Several diseases, including cancer, are typically accompanied or caused by DNA mutations and the way DNA organizes itself to form chromosomes. Such mutational processes may be influenced by the relative accessibility of the DNA to various proteins and by the organization of the DNA in the cell nucleus. Therefore, the scientists believe that the nucleosome positioning code they discovered may aid scientists in the future in understanding the mechanisms underlying many diseases.

Until Dr. Eran Segal, from the Rehovot institute's computer science and applied mathematics department, and research student Yair Field came to their conclusions together with colleagues from Chicago's Northwestern University, no one knew what determined how, when and where a nucleosome would be positioned along the DNA sequence.

Nucleosomes, which resemble "beads on a string of DNA" when observed through an electron microscope, are known to play an important role in the cell's day-to-day function. Access to DNA wrapped in a nucleosome is blocked for many proteins, including those responsible for some of life's most basic processes. Among these barred proteins are factors that trigger DNA replication, transcription and repair. The positioning of nucleosomes defines the segments in which these processes can and can't take place.

These limitations are significant, as most of the DNA is packaged into nucleosomes. A single nucleosome contains about 150 genetic bases (the "letters" that make up a genetic sequence), while the free area between neighboring nucleosomes is only about 20 bases long. It is in these nucleosome-free regions that processes such as transcription can be initiated.

For many years, scientists had been unable to agree on whether the placement of nucleosomes in living cells was controlled by the genetic sequence itself. Segal's team managed to prove that the DNA sequence indeed encodes "zoning" information on where to place nucleosomes. They also characterized this code and then, using the DNA sequence alone, were able to accurately predict a large number of nucleosome positions in yeast cells.

Since the proteins that form the core of the nucleosome are among the most conserved in nature by evolution, the scientists believe the genetic code they identified is also conserved in many organisms, including humans.

To unravel the code, the scientists examined 200 different nucleosome sites on DNA to determine whether the sequences around them had something in common. Mathematical analysis revealed similarities between the nucleosome-bound sequences, and eventually uncovered a specific "code word." This "code word" consists of a periodic signal that appears every 10 bases on the sequence.

The regular repetition of this signal helps the DNA segment bend sharply into the spherical shape required to form a nucleosome. To identify this nucleosome positioning code, the research team used models of probability to characterize the sequences bound by nucleosomes and developed a computer algorithm to predict the encoded organization of nucleosomes along an entire chromosome.

The team's findings provided insight into another mystery that has long been puzzling molecular biologists: how cells direct transcription factors to their intended sites on the DNA, as opposed to the many similar but functionally irrelevant sites along the genomic sequence."

Source: Judy Siegel-Itzkovich. Weizmann team cracks code of DNA strand. JPost.com (25 July 2006) [FullText]

Labels:

Home | Archive | Rehovot.org | BizDir | rBB | rForum | Rentals | Property | Jobs | Makolet | Flowers | Car4sale | TV | Photo Albums | Arts | Events | Obituaries/Guest Books | Sport | Bulletin Board (Rus) | Dating (Rus) | Advertise | Contacts
_ _Press go button to proceed with your subscription request          This is a link to MyRehovot.Info in Russian  This is a link to MyRehovot.Info in Hebrew  This is a link to MyRehovot.Info home in English
Visit Google Scholar, new search of quality scholar literature by Google   _